Цеклор

Quick links

Choose a section

Quick links to important sections

Advertisements

Цеклор

Advertisements
Advertisements

Overview of Цеклор

Property Description
Active ingredient Cefaclor (INN)
Form Capsule, Tablet, Oral Suspension/Syrup
Pharmacological class Second-Generation Cephalosporin Antibiotic
Common use Treating Bacterial Infections
Origin Semisynthetic

What Type of Medicine is Цеклор?

Цеклор is a prescription-only antimicrobial medication, specifically classified as an antibiotic used for fighting susceptible bacterial infections. Its active component, Cefaclor, is pharmacologically categorized as a second-generation cephalosporin. This confirms that Цеклор belongs to a specific group of antibiotics effective against a wide range of bacteria. This classification places it within the larger family of β-Lactam antibiotics. As an oral, semisynthetic agent, it exhibits a broad-spectrum profile against both Gram-positive and specific Gram-negative bacteria.

Composition, Origin, and Available Forms

The therapeutic substance in this medicine is Cefaclor (INN), which often appears in its chemical form as Cefaclor monohydrate. The drug is a single active ingredient product derived as a semisynthetic compound, meaning its structure is chemically modified to enhance its stability compared to some natural derivatives. Цеклор is available for oral administration in multiple pharmaceutical preparations, including solid forms like capsules and extended-release tablets, as well as liquid forms such as oral suspension and syrup, which are used for treating pediatric patient groups. The availability of the oral suspension allows for flexible administration, supporting typical use scenarios where a liquid form is required for children or patients with difficulty swallowing.

General Purpose: Targeting Bacterial Infections

The fundamental therapeutic purpose of Цеклор is to resolve an underlying bacterial infection by initiating a bactericidal action against the responsible pathogens. This action relates to its ability to interfere with bacterial cell processes. This is achieved through its general mechanism of effect: it fundamentally prevents bacteria from building and maintaining their rigid outer protective layer, the cell wall. This process is a bactericidal action resulting from inhibition of cell-wall synthesis. This means the medication actively kills the bacteria by destroying their protective structure, a property used as a strategy for eliminating the microbial cause of illness.

Regulatory References

  1. FDA Prescribing Information
Advertisements

What side effects are possible with Цеклор?

Possible side effects and safety information

The safety profile of Цеклор (Cefaclor), a second-generation cephalosporin, is officially documented across several categories, primarily concerning allergic responses and gastrointestinal issues, as classified by government regulatory sources.


Adverse Reactions and Frequency

Adverse reactions are classified by frequency and system-organ class.

  • Common Reactions (1–10%): The most frequently reported adverse effects include diarrhea and headache. Increases in certain liver enzymes (transaminases) and infections such as moniliasis (candidiasis) are also classified as common.
  • Rare Reactions: Less frequent but documented effects include blood disorders (leukopenia, hemolytic anemia), severe skin reactions (Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), and reversible interstitial nephritis.

Serious Adverse Events and Safety Constraints

Officially listed serious adverse events require awareness. These include anaphylaxis (a severe allergic reaction) and severe intestinal inflammation known as pseudomembranous colitis, which may appear during or up to several weeks after cessation of treatment.

Safety documents also contain several constraints:

  • Hypersensitivity: The medicine is contraindicated in patients with a known allergy to any cephalosporin. Caution is officially advised for individuals with a history of penicillin allergy due to the potential for cross-allergenicity between these drug classes.
  • Population-Specific Notes: Serum sickness-like reactions—characterized by rash, fever, and joint pain—have been reported more frequently in children than in adult patients. Patients with renal impairment should be carefully monitored.
  • Laboratory Interference: Cefaclor can lead to a false-positive result for urine glucose using copper reduction tests and a positive Coombs' test.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Цеклор

The official regulatory profile for Цеклор (Cefaclor) overdose focuses on specific documented manifestations and mandates for emergency response.

Documented Manifestations and Risks

Overdose symptoms are officially classified as non-specific, primarily involving gastrointestinal distress such as nausea, vomiting, and epigastric distress. Diarrhea is also a listed manifestation, and the severity of the distress and diarrhea is documented as being dose-related. If symptoms beyond gastrointestinal distress arise, official labeling indicates they are likely secondary to an underlying disease state or other intoxication.

A serious, class-related outcome noted in regulatory documents is the potential for neurotoxicity, which may include seizures and encephalopathy. This risk is particularly highlighted for patients with renal impairment who exceed the recommended dose, as lack of dose adjustment is a documented concern.

Emergency Actions and Supportive Management

Seeking immediate medical attention is required upon suspected overdose. Treatment is officially stated to be mainly supportive.

Management Detail Regulatory Statement
GI Decontamination Gastric lavage is required only if ingestion is more than 5 times the normal total daily dose.
Excretion Procedures Hemodialysis, forced diuresis, and peritoneal dialysis have not been established as beneficial.
Severe Reactions Emergency measures (e.g., Epinephrine, Airway Management) are mandated for serious acute hypersensitivity reactions.
Advertisements

Therapeutic Uses of Цеклор

What Цеклор Treats: Main Uses and Benefits

Цеклор (Cefaclor) is an antibiotic used to address infections caused by susceptible bacteria, focusing on the supportive relief of acute symptoms across several key areas of the body. Its application is generally considered relevant in clinical situations where patient discomfort is high due to bacterial activity. This medication is typically used to manage conditions characterized by periods of heightened symptoms.

This includes infections of the upper and lower airways (such as pneumonia and bronchitis), ear, nose, and throat (like otitis media, pharyngitis, and tonsillitis), and the urinary tract (including cystitis and pyelonephritis), as well as skin and skin structure infections.

Цеклор supports patients during difficult episodes by easing distress, addressing symptoms related to systemic imbalance like fever, and symptoms related to inflammatory or irritative states such as localized pain or painful urination. The use is often applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

“It is commonly used to help with symptoms that create noticeable functional strain, assisting with maintaining functional stability.”

Quick Fact: Supportive Relief for Localized and Systemic Discomfort

Regulatory References

  1. NIH MedlinePlus overview on Cefaclor
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Цеклор (Cefaclor)

This section outlines the population eligibility rules for Cefaclor strictly as defined by official regulatory documents.

Eligibility scope
Populations for whom use is allowed: Adults, older adults, and pediatric patients aged 1 month and older.
Populations for whom use is contraindicated: Patients with known allergy to the cephalosporin group of antibiotics; infants under one month of age (safety and efficacy not established).
Pregnancy and lactation eligibility status: Use during pregnancy (FDA Category B) is recommended only if clearly needed. Use during lactation requires caution due to excretion of small amounts in breast milk.
Eligibility-related restrictions: Use requires caution for patients with markedly impaired renal function, a history of gastrointestinal disease (especially colitis), or a history of penicillin allergy (due to cross-hypersensitivity potential). The extended-release tablet is not approved for those under 16 years of age.

Eligibility Classifications (High-Level)

Classification
Eligibility severity classification: Formal regulatory classifications include Contraindication (Absolute exclusion) and Caution (Conditional use), as noted in labeling [Source 1.1, 4.3].

Connection to the overall eligibility profile: Regulatory documents establish the primary exclusion based on drug class allergy and clear age restrictions for infants where use is contraindicated. Furthermore, the official labeling imposes requirements for caution based on pre-existing conditions like impaired kidney function and a history of colitis, thereby defining the conditional use framework for Cefaclor.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cefaclor is defined by officially documented changes to drug exposure, additive pharmacological effects, and interference with clinical diagnostics. All information is derived strictly from government regulatory documentation.


Pharmacokinetic and Exposure Interactions

Co-administration of Probenecid is officially documented to increase and prolong the systemic exposure and serum concentration of Cefaclor. This is due to a transporter-mediated pharmacokinetic interaction where Probenecid inhibits the renal tubular secretion of Cefaclor.

When the immediate-release form is taken with food, the rate of absorption is officially reduced, causing a lower and delayed peak plasma concentration ( C max). However, the total amount of drug absorbed (AUC) remains unchanged.


Pharmacodynamic and Clinical Risk

The co-administration of Cefaclor with oral anticoagulants, such as Warfarin, is associated with a risk of increased prothrombin time and potential bleeding. Regulatory documentation requires monitoring of prothrombin time for patients receiving this combination. There is a documented potential for additive toxicity when Cefaclor is combined with other agents known to affect the kidneys, such as Aminoglycoside Antibiotics, carrying a risk of nephrotoxicity.


Laboratory and Population-Specific Notes

Cefaclor use may result in a false-positive direct Coombs' test and can cause false-positive results in urinary glucose tests that rely on copper reduction methods. A population-specific note is documented regarding patients with severe renal impairment (anuria), in whom the drug's plasma half-life is officially prolonged.

Advertisements

Mechanism of Action

Цеклор (Cefaclor) operates by precisely interfering with the structural integrity of susceptible bacterial cells. The mechanism is centered on two core domains that initiate the destruction of the microbial cell.

Targeting Bacterial Cell Wall Enzymes (PBPs)

This mechanism targets the Penicillin-Binding Proteins (PBPs), which are bacterial transpeptidase enzymes required for the final stages of cell wall construction. Цеклор functions as an irreversible inhibitor by binding covalently to the active site of these PBPs. This molecular action immediately blocks the critical cross-linking step of peptidoglycan synthesis, which is necessary for building a rigid, stable cell wall.

The Bactericidal Lysis Cascade

The consequence of PBP inhibition is the initiation of a cellular lysis cascade. Without correctly cross-linked peptidoglycan, the newly formed bacterial cell wall becomes structurally defective and severely weakened. This structural failure leads to the cell's inability to withstand its high internal osmotic pressure, causing it to lyse (rupture). This destructive process results in the bactericidal lysis of susceptible bacterial cells, thereby achieving the death of the susceptible cell.

Advertisements

Dosage and Administration Information

How to Use Цеклор: Official Administration Guidelines

Цеклор (Cefaclor) is an antimicrobial medication administered solely via the oral route. It is available in immediate-release capsules, liquid oral suspension, and extended-release (ER) tablets.


Dosing and Schedule

The standard adult dosage is typically 250 mg every 8 hours (TID). For more severe infections, the dose may be doubled to 500 mg every 8 hours, though the usual therapeutic limit is 2 g per day. Extended-release tablets are generally taken every 12 hours.

For pediatric patients (ages 1 month and older), the typical dosage is 20 mg/kg/day divided and given every 8 hours. This may be increased to 40 mg/kg/day for conditions like otitis media, with a maximum limit of 1 g/day.


Administration Conditions and Duration

Immediate-release forms can be taken with or without food; however, the extended-release tablet must be taken within 1 hour of eating a meal to optimize absorption.

Treatment is commonly prescribed for a period of 7 to 10 days. For infections caused by beta-haemolytic streptococci, the official instruction mandates that administration must continue for a minimum of 10 days. If a dose is missed, it should be taken as soon as possible unless it is almost time for the next dose, in which case the missed dose should be skipped; doses must not be doubled.


Special Handling

Extended-release tablets must be swallowed whole and must not be crushed, chewed, or split. The oral suspension requires reconstitution with water and must be shaken well before each use.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Цеклор (Cefaclor)


Evidence for Use in Acute Ear and Respiratory Infections

Research has been conducted on the use of Cefaclor in treating acute infections that cause episodic or acute changes in the ear and upper airways. The evidence base includes Randomized Controlled Trials (RCTs) and controlled clinical trials, primarily focusing on pediatric populations. Studies examined outcomes related to physical discomfort and outcomes related to systemic or functional imbalance, such as fever. Findings describe patterns observed in these studies related to how symptoms evolved and the microbiological outcomes.

For Upper Respiratory Tract Infections, research monitored the clearance of specific pathogens. However, a key limitation is that limited information is available for long-term outcomes, particularly concerning whether Cefaclor treatment was associated with the subsequent prevention of complications like rheumatic fever, which is not fully established.


Evidence for Use in Urinary Tract Infections (UTI) and Skin Infections

Cefaclor was studied for use in Urinary Tract Infections, where research examined outcomes linked to inflammatory states, such as patient-reported outcomes describing perceived discomfort, and tracked microbiological outcomes. Research has highlighted a significant limitation concerning increasing bacterial resistance among common UTI pathogens, which may impact the relevance of historical study results.

For Skin and Skin Structure Infections, trials observed patient responses, documenting patterns of clinical status following the short-term course of treatment. Comparative evidence for these conditions is limited when assessed against newer agents, and alternative treatments are often cited in contemporary guidelines.


Research Gaps and Follow-up Duration

Clinical trials were primarily designed as short-term intervention studies. Follow-up durations were limited across many key trials, meaning that long-term effects on chronic health, recurrence rates, or the durability of the response are not fully established. Research highlights that data for certain groups remain insufficient, such as for older adults with significant kidney impairment. The existing evidence is largely derived from settings with varying symptom burdens over defined, short time intervals.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цеклор (FAQ)


Q: How quickly does Цеклор typically begin to work after the first dose?

According to official patient information, improvement in symptoms is generally expected to be felt within the first few days of starting treatment. It is important to remember that this is a general expectation and individual responses may vary.


Q: What are the components of Цеклор that cause it to stop the growth of bacteria?

The active substance is Cefaclor, which is classified as a beta-lactam antibiotic. This class of medicine operates by interfering with the necessary building of the bacterial cell wall structure.


Q: What are the signs of a serious allergic reaction to Цеклор that require immediate attention?

Official documentation notes that severe allergic events, known as anaphylactoid reactions, are listed as events requiring medical review. These signs can include swelling of the face, limbs, or tongue (angioedema), difficulty breathing, and fainting (syncope).


Q: What is the reported risk of developing severe diarrhea (like C. difficile infection) while on Цеклор?

Severe intestinal inflammation, known as pseudomembranous colitis, has been reported with this medication. This condition is listed in regulatory documentation as a serious adverse event, with symptoms that may appear either during treatment or up to several weeks after stopping the medicine.


Q: What is the official guidance on consuming alcohol while undergoing treatment with Цеклор?

Official health body information indicates that Cefaclor is not documented to have a direct chemical interaction with alcohol. Patients are encouraged to discuss alcohol use with their healthcare professional.


Q: What is the general difference between the regular capsule form and the extended-release tablet form of Цеклор?

The primary difference lies in how the medicine is released into the body. The extended-release form is specifically designed to allow the body to maintain the medicine's concentration for a longer period of time compared to the immediate-release capsule.


Q: Why is it important for a doctor to monitor blood work if Цеклор is taken for an extended period?

Regulatory documents recommend the monitoring of renal (kidney) and hematological (blood) status during prolonged or high-dose treatment. This practice addresses the potential for rare effects on blood cell counts and kidney function.


Q: Is Цеклор intended for use against viral infections, such as the common cold or flu?

Цеклор is classified as an antibiotic and is intended only for fighting susceptible bacterial infections. Antibiotics are intended for bacterial infections and do not target viruses, which cause the common cold and flu.


Q: Can Цеклор cause a rash, and how is a severe rash distinguished from a mild one?

Rashes are reported as allergic reactions in approximately 1.7% of patients. While a mild rash is often minor, a severe reaction, such as Stevens-Johnson syndrome, is characterized by symptoms like widespread peeling or blistering of the skin and is an event that requires medical review.


Q: Does taking Цеклор commonly cause headache or dizziness?

Official reports indicate that headache is classified as a common adverse reaction (occurring in 1–10% of patients). Dizziness and somnolence (drowsiness/sleepiness) have also been reported, but far less frequently, as rare reactions.


Q: Can Цеклор cause a yeast infection (thrush) in women or men?

Yes, infections such as moniliasis (candidiasis), commonly known as a yeast infection or thrush, are classified as common adverse reactions. This occurs because antibiotics can alter the body’s natural balance of microbes.


Q: How long do common side effects from Цеклор typically last?

For most allergic reactions like rashes or hives (urticaria), the symptoms usually subside within a few days of stopping the medication. However, official information notes that in rare instances, certain hypersensitivity symptoms may persist for several months.


Q: Does Цеклор have a potential link to joint pain or stiffness?

A specific reaction called serum sickness-like reaction has been documented, which includes symptoms such as rash, fever, and joint pain (arthralgia/arthritis). This reaction has been reported more frequently in children.


Q: Can Цеклор affect urine sugar test results for patients with diabetes?

Yes, regulatory information states that Cefaclor can cause a false-positive result in urine glucose tests that use copper reduction methods (such as Benedict’s or Fehling’s solutions). This is a known laboratory interference effect.


Q: Does Цеклор interact with hormonal contraceptives like birth control pills?

Regulatory information indicates that antibiotics, including Cefaclor, may potentially reduce the effectiveness of hormonal contraceptives in some women. Consultation with a healthcare professional regarding appropriate precautions is referenced in official information.


Q: Can the effectiveness of vaccines, such as the Typhoid vaccine, be reduced by Цеклор?

Yes, Cefaclor may prevent the oral Typhoid vaccine from working correctly. For this reason, official guidance suggests spacing out the antibiotic treatment and the vaccine administration.


Q: Is Цеклор generally considered safe for use during pregnancy?

Цеклор is classified by the FDA as Pregnancy Category B. This classification means that while animal studies have not shown risk to the fetus, there are no adequate, well-controlled studies in pregnant women. Official labeling states use during pregnancy is warranted only if clearly needed.


Q: Is there any information about using Цеклор while breastfeeding?

Small amounts of Cefaclor are known to be excreted into breast milk. Caution is advised because maternal doses have been associated with reports of side effects, such as diarrhea and thrush, in the nursing infant.


Q: Can older adults (age 65 and over) take Цеклор?

Older adults are included in the allowed population for this medicine. However, official labeling advises caution for all patients, including older adults, who have markedly impaired renal (kidney) function.


Q: Are there any known long-term effects associated with taking Цеклор?

Official documents highlight that prolonged use of the antibiotic may lead to the overgrowth of non-susceptible organisms. Furthermore, neurotoxicity (harm to the nervous system) has been associated with the cephalosporin class in patients with severe kidney impairment.


Q: Is it true that taking Цеклор can affect the body's natural gut flora?

Yes, the action of the antibiotic can affect the balance of the body's natural flora, especially in the gut. This change can result in the overgrowth of other organisms and is the underlying cause of common side effects like diarrhea and more serious conditions like colitis.


Q: Why do some patients report feeling tired or weak when taking Цеклор?

The adverse event profile includes rare reports of asthenia (lack of energy or weakness), somnolence (drowsiness/sleepiness), and dizziness. These effects may contribute to a general feeling of tiredness or weakness in some individuals.


Q: What is the recommendation regarding taking Цеклор around the time of an antacid?

Official patient information indicates that the overall absorption of Cefaclor may be reduced if it is taken around the same time as antacids that contain magnesium hydroxide or aluminum hydroxide.


Q: What kinds of lab tests might be affected by taking Цеклор?

Cefaclor is known to cause interference in certain laboratory tests. These include potentially producing a false-positive direct Coombs' test and false-positive results in urine glucose tests that rely on copper reduction methods.

Advertisements

How should Цеклор be stored and disposed of?

How to Store and Dispose of Cefaclor (Ceclor)

The storage and disposal instructions for Cefaclor are based on regulatory requirements to ensure product stability and safety.

Storage Requirements

Cefaclor solid forms (capsules, tablets, and dry powder) must be stored at controlled room temperature (15 C to 30 C) and protected from moisture. They should be kept in a tightly closed, light-resistant container. The medication must be kept out of the sight and reach of children.

Once the oral suspension is mixed, it must be stored in a refrigerator (not frozen). The reconstituted liquid remains stable for 14 days and any unused portion must be discarded after this period.

Disposal Instructions

Unused or expired Cefaclor should be disposed of through an official drug take-back program. If a take-back program is not available, the medicine must be mixed with an undesirable substance (e.g., dirt) in a sealed bag and placed in the household trash. Cefaclor is not recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цеклор found in:

A-Z Index: